Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention

Acta Obstetricia Et Gynecologica Scandinavica
Marie SøgaardSimon A Gayther

Abstract

The Nordic countries have the highest incidences of ovarian cancer in the world (around 15 cases per 100,000 women). We have conducted a review of the recent literature with focus on the Nordic countries, on genetic susceptibility to ovarian cancer, and the clinical implications in relation to the BRCAI and BRCA2 genes. One of the strongest risk factors for ovarian cancer is a family history of ovarian and/or early-onset breast cancer. It is thought that germline mutations in BRCA1/2 might be responsible for as much as 10% of all ovarian cancer cases and all families containing either multiple case, site-specific ovarian cancer cases or breast and ovarian cancers together. Data from several international studies suggest that the lifetime risk of ovarian cancer in a BRCA 1 mutation carrier can vary from 18 to 56% and from 14 to 27% in a BRCA2 carrier, depending on the presence/absence of a family history of the disease. Genetic evaluation and testing is used in many countries to identify families with BRCA1/2 mutations. Once a mutation has been identified, genetic counseling and testing can be offered to unaffected family members. Prophylactic oophorectomy in unaffected mutation carriers will eliminate the risk of ovarian cancer...Continue Reading

Citations

Jul 16, 2011·Hormones & Cancer·Antonio F SaadAnil K Sood
Oct 30, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GadducciR Tana
Jun 17, 2008·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·N M LinnerthR A Moorehead
Apr 26, 2007·Clinical Medicine & Research·Christopher P CrumYonghee Lee
Mar 5, 2011·Acta Obstetricia Et Gynecologica Scandinavica·Anne-Bine SkytteSteen Kølvraa
Jun 7, 2011·Biochimica Et Biophysica Acta·M G M BraemN C Onland-Moret
Jun 20, 2012·Gynecologic Oncology·Marjanka J J M MingelsMijke Bol
May 21, 2016·Frontiers in Oncology·Sophia H L GeorgeBrian M Slomovitz
Jan 13, 2010·Laboratory Investigation; a Journal of Technical Methods and Pathology·Jian-Liang ChouMichael W-Y Chan
Mar 9, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·K DomanskaM Nilbert
Mar 5, 2009·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Shannon SalvadorDianne Miller
Feb 22, 2012·Clinical Obstetrics and Gynecology·Jessica Hunn, Gustavo C Rodriguez
Dec 17, 2008·European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)·Ira M KellertMiranda J M Dirx
Dec 13, 2017·Oncotarget·Zimin Pan, Xing Xie
Nov 21, 2013·Menopause : the Journal of the North American Menopause Society·Claudia MarchettiPerluigi Bendetti Panici
Jul 17, 2010·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·Angiolo GadducciAndrea Riccardo Genazzani
Jun 19, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Marie SoegaardSusan J Ramus
Jun 6, 2007·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Marie SoegaardSusanne K Kjaer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.